Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates

AIDS

Volumn 18, Issue 12, 2004, Pages 1697-1705

  Touloumi, Giota ^a   Pantazis, Nikos ^a   Babiker, Abdel G ^b   Walker, Sarah A ^b   Katsarou, Olga ^c   Karafoulidou, Anastasia ^c   Hatzakis, Angelos ^a   Porter, Kholoud ^b,d  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b MRC HIV Clinical Trials Unit   (United Kingdom)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

CD4 cell counts; HIV; Risk group; Seroconversion; Viral load

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CELL COUNT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; HETEROSEXUALITY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; RISK FACTORS; RNA, VIRAL; SEX FACTORS; VIRAL LOAD;

EID: 4143129859     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000131395.14339.f5     Document Type: Article

References (47)

1. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
2. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
3. O' Brien TR, Blaltner WA, Waters D, Eysler E, Hilgartner MW, Cohen AR, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-110.
4. 4 cell count. JAMA 1998, 279:35-40.
5. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA 2000, 283:381-390.
6. Report of the NIH Panel to Define Principles of Therapy of HIV Infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR 1998, 47:1-82. Updated April 2001 as a living document. http://www.hivatis.org/lrtgdlns.html (accessed April 2001).
7. Anastos K, Gange S, Lau B, Weiser B, Detels R, Giorgi JV, et al. Association of race and gender with HIV-1 RNA levels and immunologic progression. J Acquir Immune Defic Syndr 2000, 24:218-226.
8. Saul J, Erwin J, Sabin C, Kulasegaram R, Peters BS. The relationships between ethnicity, sex, risk group, and virus load in human immunodeficiency virus type 1 antiretroviral-naive patients. J Infect Dis 2001, 183:1518-1521.
9. Sterling T, Vlahov D, Astemborski I, Hoover DR, Margolick JB, Quinn TC. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med 2001, 344:720-725.
10. Junghans C, Ledergerber B, Chan P, Weber R, Egger M. Sex differences in HIV-1 viral load and progression to AIDS: Swiss HIV Cohort Study. Lancet 1999, 353:589.
11. Lyles C, Vlahov D, Farzadegan H, Astemborski J, Margolick B, Masters BA, et al. Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups. J Clin Microbiol 1998, 36:3647-3652.
12. Moroni M. Sex differences in HIV-1 viral load and progression to AIDS: ICONA Study Group. Italian cohort of HIV-1 positive individuals. Lancet 1999, 353:589-590.
13. Rezza G, Lepri AC, d' Arminio Monforte A, Pezzotti P, Castelli F, Dianzani F, et al. Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. ICONA Study Group. J Acquir Immune Defic Syndr 2000, 25:56-62.
14. Napravnik S, Poole C, Thomas J, Eron J. Gender difference in HIV RNA levels: A meta-analysis of published studies. J Acquir Immune Defic Syndr 2002, 31:11-19.
15. Gandhi M, Bacchetti P, Miotti P, Quinn TC, Veronese F, Greenblatt RM. Does patient sex affect human immunodeficiency virus levels? Clin Infect Dis 2002, 35:313-322.
16. Collaborative Group on AIDS Incubation and HIV survival including in the CASCADE EU Concerted Action. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Lancet 2000, 355:1131-1137.
17. Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G and the Italian Seroconversion Study. HIV disease progression in 854 women and men infected through infection drug use and heterosexual sex and followed for up to nine years from seroconversion. BMJ 1994, 309:1537-1542.
18. Katzenslein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
19. Prins M, Veugelers PJ for the European Seroconverter Study and the Tricontinental Seroconverter Study. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. AIDS 1997, 11:621-631.
20. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR for the UK Haemophilia Centre Director's Organization. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. Lancet 1996, 347:1573-1579.
21. 6/l AIDS, and death from AIDS? BMJ 1994, 309:1535-1537.
22. Vanhems P, Lambert J, Cooper DA, Perrin L, Carr A, Hirschel B, et al. Severity and prognosis of acute human immunodeficiency virus type 1 illness: a dose-response relationship. Clin Infect Dis 1998, 26:323-329.
23. Pedersen C, Lindhardt BO, Jensen BL, Lauritzen E, Gerstoft I, Dick E, et al. Clinical course of primary HIV infection consequence for subsequent course of infection. BMJ 1989, 299:154-157.
24. CASCADE European Collaborative Project. The relationship between the HIV test interval, demographic factors and HIV disease progression. Epidemiol Infect 2001, 127:91-100.
25. Vanhems P, Allard R, Dhenain M, Chidiac C, Peyramond D, Touraine JL, et al. HIV seroconversion interval and demographic characteristics: no evidence of selection bias. Sex Transm Infect 2001, 77:446-448.
26. CASCADE Collaboration. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE. HIV Med 2000, 1:224-231.
27. Centers for Diseases Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morbid Mortal Wkly Rep 1992, 41:1-19.
28. Piatiak M, Saag M, Yang L, Clark SJ, Kappes JC, Luk KC, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993, 259:1749-1754.
29. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994, 68:4650-4655.
30. Jurriaans S, Van Gemen B, Weverling GJ, Van Strijp D, Nara P, Coutinho R, et al. The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 1994, 204:223-233.
31. Touloumi G, Pocock SJ, Babiker AG, Darbyshire JH. Impact of missing data due to selective drop-outs in cohort studies and clinical trials. Epidemiology 2002, 13:347-355.
32. Wu MC, Bailey KR. Analyzing changes in the presence of informative right censoring caused by death or withdrawal. Stat Med 1998, 7:337-346.
33. Pantazis N, Touloumi G, Walker AS, Babiker AG. Bivariate modeling of longitudinal measurements of two HIV-1 disease progression markers in the presence of informative drop-outs J R Stat Soc Ser C Appl Stat 2004, in press.
34. Touloumi G, Babiker AG, Kenward MG, Pocock SJ, Darbyshire JH. A comparison of two methods for the estimation of precision with incomplete longitudinal data, jointly modeled with a time-to-event outcome. Stat Med 2003, 22:3161-3175.
35. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1 infected individuals with well estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003, 34:76-83.
36. Kalish L, Collier A, Flanigan T, Kumar P, for the Viral Activation Transfusion Study Group. Plasma human immunodeficiency virus (HIV) type 1 RNA load in men and women with advanced HIV-1 disease. J Infect Dis 2000, 182:603-606.
37. Delmas MC, Jadand C, de Vicenzi I, Deveau C, Persoz A, Sobel A, et al. Gender difference in CD4+ cell counts persist after HIV-1 infection. AIDS 1997, 11:1071-1073.
38. Prins M, Robertson RJ, Brettle RP, Aguado IH, Broers B, Boufassa F, et al. Do sex differences in CD4 cell count matter? AIDS 1999, 13:2361-2364.
39. Ahmad K. Multiple HIV-1 variants more common in women. Lancet 2000, 355:123.
40. Institute of Medicine. Exploring the biological contributions to human health: does sex matter? 2001, http://www.nap.edu/catalog/10028.htlm
41. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use and progression of human immunodeficiency virus disease. N Engl J Med 1995, 333:751-756.
42. Farzadegan H, Hoover DH, Astemborski J, Lyles CM, Margolick JB, Markham R, et al. Sex differences in HIV-1 viral load and progression to AIDS. Lancet, 1998, 352:1510-1514.
43. Moore AL, Mocroft A, Madge S, Devereux H, Wilson D, Phillips AN, et al. Gender differences in virologic response to treatment in an HIV-positive population: a cohort study. J Acquir Immune Defic Syndr 2001, 26:159-163.
44. Moore AL, Sabin CA, Johnson MA, Phillips AN. Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study. J Acquir Immune Def Syndr 2002, 29:197-202.
45. Douek DC, McFarland RD, Keiser PH, Gage EA, Massey IM, Haynes BF, et al. Changes in thymic function with age and during the treatment og HIV infection. Nature 1998, 396:690-695.
46. Hatzakis A, Touloumi G, Karanicolas R, Karafoulidou A, Mandalaki T, Anastassopoulou C, et al. Effect of recent thymic emigrants on progression of HIV-1 disease. Lancet 2000, 355:599-604.
47. Hubert J-B, Burgard M, Dussaix E, Tamalet C, Deveau C, Le Chenadec J, et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known elate of infection. AIDS 2000, 14:123-131.